Clinical Trials Logo

Hyperuricemia clinical trials

View clinical trials related to Hyperuricemia.

Filter by:

NCT ID: NCT00325195 Completed - Gout Clinical Trials

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

Start date: May 2006
Phase: Phase 3
Study type: Interventional

These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard gout therapies, or for whom those therapies have been unsuccessful in controlling their uric acid level.

NCT ID: NCT00302653 Completed - Hyperuricemia Clinical Trials

Rasburicase in Tumor Lysis Syndrome

Start date: February 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

NCT ID: NCT00290992 Completed - Clinical trials for Nutritional and Metabolic Diseases

Rasburicase for Hyperuricemia

Start date: June 2005
Phase: Phase 2
Study type: Interventional

Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration. Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP antibodies, and pharmacokinetic parameters.

NCT ID: NCT00288158 Completed - Obesity Clinical Trials

Primary Prevention of Hypertension in Obese Adolescents

Start date: September 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are: 1. Test the hypothesis that lowering uric acid will improve endothelial function. 2. Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels. 3. Test the hypothesis that lowering uric acid will reduce markers of inflammation

NCT ID: NCT00230217 Completed - Tumors Clinical Trials

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Start date: March 2004
Phase: Phase 4
Study type: Interventional

This is an open-label, multi-center study with 2 arms. The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor malignancies, those previously treated with a uricolytic agent, and those not previously treated with a uricolytic agent at their first relapse or refractory disease.

NCT ID: NCT00230178 Completed - Cancer Clinical Trials

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Start date: April 2004
Phase: Phase 3
Study type: Interventional

This is a randomized, multi-center, open-label, parallel group study with three arms: - Rasburicase alone - Rasburicase followed by Allopurinol - Allopurinol alone The primary objective is to compare the adequacy of control of plasma uric acid concentration and the safety profile among the three arms.

NCT ID: NCT00199043 Completed - Clinical trials for Adult Acute Lymphocytic Leukemia

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Start date: May 2003
Phase: Phase 3
Study type: Interventional

In this study the efficacy and tolerability of two approaches to treat and prevent hyperuricemia is tested in patients with acute lymphoblastic leukemia or high-grade lymphoma with high risk of tumor lysis syndrome. Both arms are compared by randomisation. In one arm patients receive during pre-phase chemotherapy conventional prophylaxis with allopurinol whereas in the other arm Rasburicase is used.

NCT ID: NCT00186940 Completed - Lymphoma Clinical Trials

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Start date: March 2005
Phase: N/A
Study type: Observational

This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

NCT ID: NCT00174954 Completed - Gout Clinical Trials

Magnetic Resonance Imaging in Subjects With Gouty Tophi

Start date: March 2002
Phase: Phase 2
Study type: Observational

The purpose of this study is to determine the reproducibility of Magnetic Resonance Imaging (MRI) in the quantitative assessment of tophus volume.